FeesSafety
Pluang+

Abivax refutes short seller report, defends clinical data and FDA filing plans

Market News
20 Nov 2026, 23:33 WIB
GlobeNewsWire
View Source
Neutral
Abivax refutes short seller report, defends clinical data and FDA filing plans

Abivax, a biotech company, responded to a short seller report by Scorpion Capital released on November 20, 2026, calling it factually inaccurate and misleading. The company reaffirmed confidence in its Phase 3 clinical trials for its lead drug obefazimod and its upcoming U.S. FDA New Drug Application filing by year-end. Abivax highlighted Scorpion Capital's financial interest in a share price decline, noting the short seller's disclosed position and plans to cover part of it after the report. The company is reviewing the report in detail and plans to provide further updates.

Abivax's American Depositary Shares (ABVX) are trading at USD 75.00 on Pluang as of Nov 21, 2026 04:51 WIB. The stock has declined by 7.01% in the last day, reflecting recent market reactions. Its market capitalization stands at $7.31 billion, with a typical holding period of 18 days on the platform.

More News (ABVX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App